Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.

ABSTRACT:

Purpose

Following regional chemotherapy (RC) for melanoma, approximately 75 % of patients will progress. The role of immunotherapy after RC has not been well established.

Methods

A prospective, single-institution database of 243 patients with in-transit melanoma (1995-2013) was queried for patients who had progression of disease after RC with melphalan and subsequently received systemic immunotherapy. Fifteen patients received IL-2 only, 12 received ipilimumab only, and 6 received IL-2 followed by ipilimumab. Fisher's exact test was used to determine if there was a difference in number of complete responders after immunotherapy.

Results

With IL-2 alone, all patients progressed. After ipilimumab alone, three patients had a complete response and nine had progressive dis

SUBMITTER: Jiang BS 

PROVIDER: S-EPMC5161099 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature